Clinical-stage cancer immunotherapy provider Immatics Biotechnologies GmbH has announced the appointment of Cedrik Britten, MD, as Chief Medical Officer (CMO) effective June 1, 2020. In the role, Dr. Britten will be responsible for the global clinical development of Immatics’ pharmaceutical pipeline and will report directly to company CEO Harpreet Singh.
“We are excited about Cedrik joining Immatics. He has an extensive background in cell therapy, translational oncology, and immunology, as well as great experience in leading clinical and preclinical development programs in immuno-oncology. His appointment will complement Immatics’ existing strengths and capabilities as we continue the clinical development of our targeted immunotherapies with an emphasis on treating solid tumors through our two therapeutic modalities, Adoptive Cell Therapy and TCR Bispecifics,” commented Dr. Singh.
Dr. Britten brings over ten years of experience with drug development to the leadership team at Immatics. He joins the team after serving as Vice President and Head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline in the UK were he oversaw Oncology R&D and their cell therapy pipeline. Dr. Britten also previously served as the Vice President of R&D at German immunotherapy provider BioNTech.
“Immatics is bringing together three synergizing core elements that attracted me: excellent science, powerful proprietary technology platforms for the discovery of relevant targets, and T cell receptors tailored for use across a range of therapeutic modalities and a vibrant corporate culture focused on serving patients in need. These three cornerstones have enabled Immatics to reach a dynamic stage of growth with four ongoing clinical trials and a promising pipeline of several product candidates in development,” said Cedrik Britten.